Prognostic significance of secondary cytogenetic alterations in follicular lymphomas

Genes, Chromosomes & Cancer
Nathalie A JohnsonD E Horsman

Abstract

Follicular lymphoma (FL) is an indolent lymphoma with a long median survival. Transformation to a more aggressive histology (TLy) is a major cause of mortality. The critical events leading to TLy are unknown. We assessed the prognostic significance of secondary cytogenetic alterations on overall survival (OS) and transformation from 210 diagnostic FL biopsies. We analyzed serial and transformed karyotypes for recurrent alterations that predict transformation. Over 10 years, 31% of cases developed TLy. The only alteration in diagnostic karyotypes that correlated with an inferior OS was an additional X chromosome in males only (P = 0.005) suggesting that other mechanisms including epigenetic factors and over-expression of genes on the X chromosome may play a role in FL pathogenesis. In transformed karyotypes, 8q24 (MYC) translocations were common (14/37) and resulted in a median survival of 3 months posttransformation (P = 0.01). In serially obtained biopsies (28 pts), 43% of the later biopsies lacked the cytogenetic alterations found in the original FL karyotype, suggesting that karyotypic progression of FL is not strictly linear in all cases. Consequently, studying clonal evolution in FL using serial biopsies may not represent ...Continue Reading

References

Mar 1, 1987·Cancer Genetics and Cytogenetics·U KristofferssonF Mitelman
Jan 8, 1987·The New England Journal of Medicine·J J YunisM Arnesen
Dec 6, 1984·The New England Journal of Medicine·S J Horning, S A Rosenberg
Mar 28, 1998·Leukemia & Lymphoma·G K JamesR D Gascoyne
May 20, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N MacphersonR D Gascoyne
Jun 22, 2000·Genes, Chromosomes & Cancer·H L McDonaldC J Brown
Mar 10, 2001·Genes, Chromosomes & Cancer·D E HorsmanR D Gascoyne
Jun 22, 2002·Proceedings of the National Academy of Sciences of the United States of America·Izidore S LossosRonald Levy
Jan 21, 2004·Genes, Chromosomes & Cancer·Mattias HöglundDouglas E Horsman
Feb 26, 2004·Nature Genetics·Adrian S IshkanianWan L Lam
May 6, 2004·Blood·Philippe Solal-CélignyEmili Montserrat
Nov 19, 2004·The New England Journal of Medicine·Sandeep S DaveLouis M Staudt
Mar 18, 2005·Nature·Mark T RossDavid R Bentley
Sep 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daphne de Jong
Feb 6, 2007·British Journal of Haematology·Andrew J DaviesT Andrew Lister
Mar 9, 2007·Nature·Christopher GreenmanMichael R Stratton
May 9, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Silvia MontotoT Andrew Lister
Aug 19, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Charles W RossSami N Malek
Dec 22, 2007·Nature Reviews. Immunology·Ulf Klein, Riccardo Dalla-Favera
Oct 8, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Abdulwahab J Al-TourahJoseph M Connors

❮ Previous
Next ❯

Citations

Jun 24, 2010·Current Opinion in Hematology·David WrenchJude Fitzgibbon
Apr 17, 2012·Current Opinion in Hematology·R Coleman Lindsley, Ann S LaCasce
Oct 2, 2012·The Journal of Clinical Investigation·Robert KridelRandy D Gascoyne
Jun 11, 2011·Best Practice & Research. Clinical Haematology·E LeichA Rosenwald
Jan 18, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Laurie H SehnGinna G Laport
Aug 25, 2012·TheScientificWorldJournal·Luca ArcainiStefano Luminari
Apr 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas RelanderRandy D Gascoyne
Apr 13, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Silvia Montoto, Jude Fitzgibbon
Jan 21, 2017·Epigenetics : Official Journal of the DNA Methylation Society·Koorosh KorfiJude Fitzgibbon
Jan 24, 2018·The Journal of Pathology·Fong Chun ChanChristian Steidl
May 20, 2020·Leukemia & Lymphoma·Lucy PickardJessica Okosun
May 10, 2017·Expert Review of Molecular Diagnostics·Béatrice GrangePierre Sujobert
Jun 23, 2021·British Journal of Haematology·Lucile BussotSylvain Carras

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.